Alamar Keeps 2026 Revenue Guidance at $116 Million to $120 Million After Strong First-Half Growth
Key Facts
It could not be verified that Alamar Biosciences raised its 2026 revenue forecast or reported third-quarter results, as no reliable public earnings statement confirming those developments was available. The company’s latest announced financial guidance put annual revenue at $116 million to $120 million, with 59% growth at the midpoint compared with 2025. The company announced this range on August 10, 2026, as part of its second-quarter results. These estimates therefore remain the latest documented basis in the available evidence for assessing the company’s outlook. Management is scheduled to hold a third-quarter earnings call on November 3.
Second-quarter results showed revenue of $29.4 million, up 82% from $16.2 million in the same period a year earlier. The company said consumables revenue rose 147% to $15.5 million, from $6.3 million a year earlier. Alamar attributed the increase mainly to strong demand for multiplex panels. These figures provide context on sales momentum ahead of the third-quarter results. They do not establish third-quarter revenue or its growth rate.
The company posted a gross margin of 60% in the second quarter, compared with 53% in the same period of 2025. Alamar linked the improvement to manufacturing efficiencies in consumables and a more favorable mix toward higher-margin products. In the same period, net loss was $13.2 million, compared with $7.0 million a year earlier. The results show revenue growth and margin improvement coinciding with continued net losses. Third-quarter margin and loss figures could not be verified in the available evidence.
In the first quarter of 2026, revenue was $26.0 million, up 99% from $13.1 million in the same period a year earlier. Chief Executive Yuling Lu said the company started the year with a record quarter and that its NULISA platform was gaining rapid traction among academic research and biopharma customers. Consumables revenue also rose 178% to $14.0 million, from $5.0 million in the first quarter of 2025. The company attributed this mainly to sales tied to a larger installed base of instruments, along with a slight increase in the average selling price of consumables. These results provide context for first-half growth without resolving third-quarter performance.
Alamar completed its initial public offering in April 2026, generating net proceeds of $197.8 million after underwriting commissions and discounts and other expenses. On losses, the company reported a first-quarter net loss of $21.3 million, including an $8.6 million loss related to remeasurement of convertible notes, compared with a $7.7 million loss in the first quarter of 2025. This differed from the second-quarter loss, which was $13.2 million. The available quarterly figures put the growth trajectory alongside the losses, while an update to annual guidance remains unsubstantiated by the evidence.
The company said the third-quarter earnings call would begin after the market closes on Tuesday, November 3, 2026, at 1:30 p.m. Pacific time, or 4:30 p.m. Eastern time. In trading on November 2, ALMR shares closed at $28.94, according to EL7 data. The call date follows the company’s earlier announcement of it on October 8. The available evidence did not include verified third-quarter results or a new 2026 guidance figure.